Nexcella, Inc., a subsidiary of Immix Biopharma, Inc.
(“Nexcella”, “Company”, “We” or “Us”), announced that
effective today, Mary Sue Coleman, former Independent Director of
Johnson & Johnson (“J&J”), has been appointed to the
Company’s Board of Directors. Ms. Coleman brings deep experience as
a former Independent Director of Johnson & Johnson for over a
decade from 2003-2016, chairing the J&J Audit Committee; as a
member of the Audit Committee and a member of the J&J
Technology/Science/R&D Committee.
After joining the University of Michigan in 2002, Dr. Coleman
was President of the University of Michigan from 2002 until her
retirement in 2014, where she was named one of “10 Best College
Presidents” by TIME Magazine and served as President of the
University of Michigan Health System. Dr. Coleman led "The Michigan
Difference," a campaign to raise $2.5 billion. At its conclusion in
2008, the campaign finale stood at $3.2 billion – the most ever
raised by a public university at the time. Prior, Dr. Coleman was
President of the University of Iowa from 1995-2002.
“We are honored to have Dr. Coleman join our Board of Directors.
She is an experienced former Johnson & Johnson board member and
a proven leader of large research-focused institutions with a
global footprint, having successfully built and raised capital for
world-class biomedical research ecosystems,” said Ilya Rachman, MD,
Ph.D., Chief Executive Officer of Immix Biopharma. Gabriel
Morris, ImmixBio Chief Financial Officer, added: “Dr. Coleman has
deep experience in healthcare as the former President of the
University of Michigan Health System and a trustee of the Mayo
Clinic. Dr. Coleman’s leadership and skills in our industry, as
well as Dr. Coleman’s contributions to national and international
scientific endeavors, are internationally recognized. We look
forward to her valued insights as we progress NXC-201, what we
believe is the world’s first outpatient CAR-T cell therapy, through
clinical development in AL amyloidosis and multiple myeloma.”
“I have been fortunate to have a wide-ranging of experience in
my career leading public American universities, participating on
corporate boards, and contributing to the sciences broadly. This
experience makes joining the Nexcella board of directors a natural
fit,” said Dr. Coleman. “I look forward to working with the
Nexcella team to accomplish its goal of bringing innovative cell
therapies for oncology and other indications to patients.”
President Obama selected Dr. Coleman to help launch the Advanced
Manufacturing Partnership, a national effort bringing together
industry, universities and the federal government. In 2010, U.S.
Commerce Secretary Gary Locke named Dr. Coleman co-chair of the
National Advisory Council on Innovation and Entrepreneurship. Dr.
Coleman is Trustee Emerita of the Mayo Clinic; Trustee Emerita of
the Gerald R. Ford Foundation; Trustee Emerita of the Gates
Cambridge Scholarship program; Trustee Emerita, John S And James L
Knight Foundation; Trustee, Kavli Foundation; Trustee, University
of Denver; Chair of the Board of Trustees of Society for Science;
former President of the Association of American Universities;
former Board of Governors, National Collegiate Athletic Association
(NCAA); Fellow of the American Academy of Arts and Sciences; and
Fellow of the American Association for the Advancement of Science.
Dr. Coleman was elected to the National Academy of Medicine
(formerly the Institute of Medicine) in 1997. Dr. Coleman served as
Independent Director at Meredith Corporation from 1997 to 2016 and
is a former Director of Gaylord Container Corp. Earlier in
Dr. Coleman’s career, she was Provost at the University of New
Mexico; Vice Chancellor at the University of North Carolina at
Chapel Hill; and a member of the biochemistry faculty and an
administrator at the Cancer Center of the University of Kentucky in
Lexington where she built a distinguished academic career through
her teaching and research on the immune system and malignancies.
Dr. Coleman holds honorary doctorates from a number of
institutions including Grinnell College, Dartmouth College, Notre
Dame University, the University of North Carolina, Indiana
University and Michigan State University. She is the
recipient of distinguished alumnus awards from the University of
North Carolina and Grinnell College. The Michigan Roundtable for
Diversity and Inclusion honored her as Humanitarian of the Year,
and the Michigan Women’s Foundation presented her with its Trillium
Lifetime Achievement Award. Dr. Coleman earned her
undergraduate degree in chemistry from Grinnell College and a Ph.D.
in biochemistry from the University of North Carolina at Chapel
Hill.
About Nexcella, Inc.Nexcella, Inc., a
subsidiary of Immix Biopharma, Inc (Nasdaq:IMMX), is a Los Angeles,
CA based clinical-stage biopharmaceutical company engaged in the
discovery and development of novel cell therapies for oncology and
other indications. Our lead candidate, next generation
BCMA-targeted CAR-T NXC-201 for multiple myeloma and AL amyloidosis
has produced 92% and 100% response rates in each indication,
respectively, as of February 9, 2023 across 58 patients. We believe
NXC-201 has potential to be the world’s first outpatient CAR-T. Our
N-GENIUS platform allows us to discover, develop, and manufacture
cutting-edge cell therapies for patients in need. To learn more
about Nexcella, Inc. visit us at www.nexcella.com.
About Immix Biopharma, Inc.Immix Biopharma,
Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage
biopharmaceutical company pioneering a novel class of CAR-T cell
therapies and Tissue-Specific Therapeutics (TSTx) targeting
oncology and immuno-dysregulated diseases with >75 patients
treated to-date. Our lead cell therapy asset is NXC-201 in multiple
myeloma and AL Amyloidosis, which we believe could be the world’s
first out-patient CAR-T. Our lead TSTx asset IMX-110, currently in
Phase 1b/2a clinical trials as a monotherapy and IMMINENT-01
combination clinical trial with BeiGene’s anti-PD-1 antibody
tislelizumab, holds Orphan Drug Designation (ODD) and Rare
Pediatric Disease Designation (RPDD) by the FDA. ImmixBio
subsidiary Nexcella, Inc develops CAR-T NXC-201 for multiple
myeloma and AL amyloidosis, with 92% and 100% response rates in
each indication, respectively, as of February 9, 2023, currently
being trialed in NEXICART-1. Learn more at www.immixbio.com.
Forward Looking StatementsThis press release
contains “forward-looking statements” Forward-looking statements
reflect our current view about future events. When used in this
press release, the words “anticipate,” “believe,” “estimate,”
“expect,” “future,” “intend,” “plan,” or the negative of these
terms and similar expressions, as they relate to us or our
management, identify forward-looking statements. Such statements,
include, but are not limited to, statements contained in this press
release relating to our business strategy, our future operating
results and liquidity and capital resources outlook.
Forward-looking statements are based on our current expectations
and assumptions regarding our business, the economy and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict. Our actual
results may differ materially from those contemplated by the
forward-looking statements. They are neither statements of
historical fact nor guarantees of assurance of future performance.
We caution you therefore against relying on any of these
forward-looking statements. Important factors that could cause
actual results to differ materially from those in the
forward-looking statements include, without limitation, our ability
to raise capital to fund continuing operations; our ability to
protect our intellectual property rights; the impact of any
infringement actions or other litigation brought against us;
competition from other providers and products; our ability to
develop and commercialize products and services; changes in
government regulation; our ability to complete capital raising
transactions; and other factors relating to our industry, our
operations and results of operations. Actual results may differ
significantly from those anticipated, believed, estimated,
expected, intended or planned including: the uncertainties related
to market conditions and other factors described more fully in the
section entitled ‘Risk Factors’ in Immix Biopharma’s Annual Report
on Form 10-K for the year ended December 31, 2022, and other
periodic reports filed with the Securities and Exchange Commission.
Any forward-looking statements contained in this press release
speak only as of the date hereof, and Immix Biopharma, Inc.
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
Factors or events that could cause our actual results to differ
may emerge from time to time, and it is not possible for us to
predict all of them. We cannot guarantee future results, levels of
activity, performance or achievements.
ContactsStern Investor RelationsSuzanne
MessereManaging DirectorSuzanne.Messere@sternir.com
Company Contactirteam@immixbio.com
Immix Biopharma (NASDAQ:IMMX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Immix Biopharma (NASDAQ:IMMX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024